J&J Pipeline Includes Contact Lens That Delivers Drugs, AF Catheter
This article was originally published in The Gray Sheet
Johnson & Johnson's late-stage development projects include a combination product for eye allergies in Phase III trials
You may also be interested in...
Johnson & Johnson/Cordis: Sales of Cypher sirolimus-eluting coronary stents in the United States declined 44% from a year ago to $185 million in the third quarter, the firm reports Oct. 16. Internationally, sales of the device were off 40% to $190 million. The firm blamed reduced percutaneous coronary intervention procedure volumes, a decreased penetration rate for drug-eluting stents versus bare-metal stents, and burgeoning overseas competition. The drug-eluting stent market has declined by over 40% in the United States and over 10% internationally, J&J estimates. The firm believes its share of the U.S. market has been stable at about 46%, while international share of 37% was down from 51% a year ago. Worldwide, Cypher's market share is about 41%, the firm says. Overall, J&J's medical devices and diagnostics segment reported Q3 sales of $5.2 billion, up 6% from a year ago. Company-wide, the diversified drug and medical technology firm generated revenue of $15 billion, up 12.7% from a year ago
With Johnson & Johnson expected to launch its Realize adjustable gastric band in the United States by the end of the year, what physicians and analysts consider a highly underpenetrated market will finally have some competition
Accelerated Approval Drugs’ Fate Rests Heavily On Current Therapeutic Landscape When Confirmatory Trials Are Overdue
At advisory committee meeting on Acrotech's two peripheral T-cell lymphoma drugs, FDA reviewers suggest they are more willing to seek product withdrawal for failure to conduct studies with due diligence when there are numerous available therapies.